List of Excipients in Branded Drug ISOVUE-M

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bracco Diagnostics Inc	ISOVUE-M	iopamidol	0270-1411	EDETATE CALCIUM DISODIUM
Bracco Diagnostics Inc	ISOVUE-M	iopamidol	0270-1411	TROMETHAMINE
General Injectables & Vaccines Inc	ISOVUE-M 200	iopamidol	52584-411	EDETATE CALCIUM DISODIUM
General Injectables & Vaccines Inc	ISOVUE-M 200	iopamidol	52584-411	TROMETHAMINE

ISOVUE-M Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

ISOVUE-M is a legacy, injectable iopamidol contrast medium used primarily for intrathecal myelography. Its excipient strategy is clinically conservative: a small excipient package supports pH control, chelation of trace metals, chemical stability, and compatibility with parenteral administration. The main commercial opportunity is not a novel excipient claim. It is supply reliability, container-closure performance, contract manufacturing, hospital procurement, and differentiated delivery formats.

ISOVUE-M contains iopamidol, tromethamine, edetate calcium disodium, hydrochloric acid or sodium hydroxide for pH adjustment, and Water for Injection. The product is supplied in iodine concentrations of 200 and 300 mg iodine/mL, according to FDA labeling.[1]

What is ISOVUE-M and who manufactures it?

ISOVUE-M is an injectable formulation of iopamidol manufactured and marketed by Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Group. Iopamidol is a nonionic, water-soluble, low-osmolar iodinated contrast agent.

ISOVUE-M is distinct from Bracco's broader ISOVUE product family, which includes formulations for intra-arterial, intravenous, and other radiographic procedures. The "M" designation identifies formulations labeled for intrathecal use.

ISOVUE-M product profile

Attribute	ISOVUE-M
Active ingredient	Iopamidol
Drug class	Nonionic, low-osmolar iodinated contrast medium
Route	Intrathecal
Primary use	Myelography, including conventional and CT myelography
Strengths	200 and 300 mg iodine/mL
Manufacturer	Bracco Diagnostics Inc.
Dosage form	Sterile injectable solution
Preservative status	Single-dose, preservative-free presentation
FDA pathway	Approved drug product under an NDA
Principal market	Hospitals, imaging centers, radiology departments, neuroradiology

The product label restricts use to trained personnel familiar with the procedure and warns against intrathecal administration of formulations not labeled for that route.[1]

What excipients are in ISOVUE-M?

The ISOVUE-M excipient system is designed to preserve a sterile, stable, injectable solution without adding unnecessary formulation complexity.

Excipient composition and function

Excipient or formulation component	Function in the formulation	Commercial significance
Tromethamine	Buffer and pH-control agent	Supports formulation stability within the labeled pH range
Edetate calcium disodium	Chelating agent	Binds trace metal ions that can promote degradation or discoloration
Hydrochloric acid	pH adjustment	Used to establish the target formulation pH
Sodium hydroxide	pH adjustment	Used to establish the target formulation pH
Water for Injection	Solvent and vehicle	Provides the sterile aqueous injection medium
Iopamidol	Active pharmaceutical ingredient	Provides radiopacity through organically bound iodine

The listed excipients are conventional parenteral ingredients. Their value lies in formulation performance and regulatory familiarity rather than exclusivity. The product is an aqueous solution, not a suspension or emulsion, so it does not require surfactants, suspending agents, viscosity modifiers, or lipid excipients.

How does the ISOVUE-M excipient strategy support stability?

The formulation has four primary technical objectives.

First, tromethamine provides buffering capacity. A controlled pH is important for minimizing chemical instability and maintaining compatibility with the intrathecal route.

Second, edetate calcium disodium reduces the impact of trace metals. Metal contamination can catalyze oxidative or other degradation pathways in pharmaceutical solutions. Chelation is therefore a low-concentration control strategy that can improve robustness across raw materials, manufacturing equipment, and packaging components.

Third, the use of Water for Injection and a limited excipient set reduces the number of variables affecting osmolality, extractables, leachables, and tolerability.

Fourth, the formulation avoids antimicrobial preservatives. That is commercially important for intrathecal products because single-dose, preservative-free presentations are preferred for neuraxial administration.

The formulation does not create a major technical barrier by itself. A competing manufacturer with access to pharmaceutical-grade iopamidol, validated sterile processing, suitable packaging, and an approved intrathecal label could reproduce the general formulation architecture. The regulatory burden remains substantial because the product is sterile, injectable, and administered into the central nervous system.

What formulations are protected by ISOVUE-M?

ISOVUE-M's commercially relevant protection is more likely to arise from regulatory approval, manufacturing know-how, product-specific labeling, and container-closure controls than from a durable excipient patent estate.

The core formulation uses established excipients and does not appear, based on the public product profile, to depend on a proprietary excipient platform. Potentially protectable subject matter could include:

• Specific iopamidol concentration and excipient ratios.
• pH and osmolality ranges.
• Stability specifications.
• Sterile manufacturing parameters.
• Container-closure configurations.
• Low-endotoxin control strategies.
• Packaging and labeling for intrathecal administration.
• Manufacturing processes that control particulate matter or trace-metal contamination.

A competitor would not necessarily need to copy each formulation parameter. It could pursue a different but pharmaceutically equivalent formulation, subject to FDA requirements for quality, safety, efficacy, and route-specific labeling.

What is the Orange Book status of ISOVUE-M?

ISOVUE-M is an older approved drug product. The FDA Orange Book, rather than the product label alone, is the controlling source for current patent-listing and exclusivity information.[2]

For an older iopamidol injection product, the principal commercial question is whether any unexpired patents or regulatory exclusivities remain relevant to an ANDA applicant. The original product approval and any early formulation patents would generally have long expiration histories, but current Orange Book entries must be checked by product-specific NDA and strength.

Exclusivity and patent considerations

Issue	ISOVUE-M assessment
New chemical entity exclusivity	Expired
Original approval exclusivity	Expired
Pediatric exclusivity	No current commercial relevance identified
Orphan exclusivity	Not the principal protection for this product
Formulation-patent risk	Must be confirmed against current Orange Book listings and public patent records
Method-of-use patent risk	Intrathecal use claims require product- and patent-specific review
Paragraph IV exposure	Possible for any ANDA referencing an active listed patent, but no conclusion should be drawn without current Orange Book data
Biosimilar risk	Not applicable; iopamidol is a small-molecule drug
Regulatory barrier	High because the product is sterile and labeled for intrathecal administration

A generic applicant may face a higher practical barrier than the absence of a major formulation patent suggests. Sterility assurance, particulate control, endotoxin limits, iodine concentration, osmolality, pH, container integrity, and route-specific clinical labeling all require disciplined development.

When does ISOVUE-M lose exclusivity?

ISOVUE-M's conventional market exclusivity has already expired because iopamidol is an established small-molecule contrast agent with an old FDA approval history. The commercial risk therefore comes from generic competition and procurement substitution, not from an approaching loss of exclusivity date.

The relevant timeline is:

Period	Commercial event
Initial launch era	Bracco establishes iopamidol as a nonionic iodinated contrast product
Post-approval period	Product-specific formulation, manufacturing, and labeling protections may apply
Patent expiration period	Early composition and formulation protections lose force over time
Current market	Competition depends on approved alternatives, supply reliability, price, contracts, and physician familiarity

A precise expiration date for each potentially relevant patent requires a verified patent-family and Orange Book review. The FDA label and Orange Book should be used together because the label identifies the approved product, while the Orange Book identifies listed patent and exclusivity information.[1,2]

What generic entry risks exist for ISOVUE-M?

Generic entry risk is meaningful but concentrated in technically capable manufacturers.

Key generic development barriers

Intrathecal labeling

Intrathecal administration creates a narrower safety margin than routine intravenous use. A manufacturer seeking approval must demonstrate that its product is suitable for the labeled route and does not introduce unacceptable excipient, particulate, endotoxin, or container risks.

Sterile manufacturing

The product requires aseptic processing or validated terminal sterilization where feasible, container-closure integrity testing, particulate controls, and release testing. These requirements increase capital and operating costs relative to nonsterile oral dosage forms.

API sourcing

Iopamidol is a specialized iodinated contrast API. Reliable access to qualified API supply, iodine-content consistency, impurity control, and validated analytical methods are important competitive factors.

Product equivalence

For an injectable solution, the generic strategy may be comparatively direct when the formulation is qualitatively and quantitatively similar. Differences in excipient levels, pH, osmolality, packaging, or visible and subvisible particles can still create regulatory and technical work.

Hospital conversion risk

Even after approval, an entrant must secure hospital contracts, group purchasing organization access, distributor placement, and radiology-department acceptance. Contrast media purchasing is price-sensitive but also affected by supply continuity and established workflow.

How strong is the ISOVUE-M patent estate?

The patent estate appears commercially weaker than the manufacturing and regulatory barriers because the product is an old, conventional aqueous formulation. The principal strength of the product franchise is operational rather than patent-based.

Patent-strength assessment

Category	Relative strength	Reason
Active-ingredient composition	Low	Iopamidol is an established small molecule
Conventional excipients	Low	Tromethamine, edetate, acids, bases, and Water for Injection are widely used
Specific formulation ratios	Low to moderate	Narrow claims may be possible but are design-around targets
Intrathecal method of use	Moderate historically	Route-specific safety and labeling can support commercial differentiation
Sterile manufacturing process	Moderate	Process know-how may be difficult to replicate even if not strongly patented
Packaging and container closure	Moderate	Performance and supply qualification can slow substitution
Brand and customer relationships	Moderate	Bracco's installed base and procurement position support retention
Regulatory approval	High practical value	A separate approved product is required for lawful commercial substitution

No biosimilar pathway applies. Iopamidol is a small-molecule contrast agent, so competition would arise through generic or other full-application pathways rather than biosimilar interchangeability.

What commercial opportunities exist in ISOVUE-M excipients?

The strongest opportunities are adjacent to the finished product rather than replacement of its excipients.

1. Excipient and raw-material supply

Suppliers can compete for pharmaceutical-grade tromethamine, edetate calcium disodium, Water for Injection systems, and high-purity pH-adjustment reagents. The opportunity depends on qualification, dual sourcing, documentation, and reliable lot-to-lot performance.

A supplier offering lower trace-metal burden, tighter bioburden control, or stronger extractables and leachables documentation could create value without changing the approved formulation.

2. Contract manufacturing

Contract manufacturers with sterile injectable capacity may target iopamidol products where branded supply is constrained or where a generic applicant requires development and commercial filling support.

The highest-value capabilities include:

• Aseptic filling of single-dose vials or syringes.
• Container-closure integrity testing.
• Low-particulate filling operations.
• Intrathecal product experience.
• Validated cleaning and sterilization processes.
• Scalable packaging and serialization.

3. Ready-to-use delivery systems

Prefilled syringes or procedure-specific presentations could reduce preparation steps and medication-error risk. Such products would face device, stability, human-factors, and container-closure requirements, but they could command value through workflow efficiency rather than excipient innovation.

4. Packaging and logistics

Single-dose packaging, tamper evidence, temperature-controlled distribution where required, and inventory visibility are practical sources of differentiation. Contrast media are frequently purchased through institutional contracts, making dependable supply a commercial asset.

5. Formulation lifecycle management

Potential development concepts include lower-volume presentations, optimized iodine concentration, or packaging designed for specific myelography workflows. Any change must preserve intrathecal safety, osmolality, pH, sterility, and approved-use requirements.

How does ISOVUE-M compare with competing contrast agents?

ISOVUE-M competes within the broader market for nonionic iodinated contrast media, including iopamidol, iohexol, iopromide, and ioversol products. Many competing products are optimized for intravenous or intra-arterial use rather than intrathecal administration.

Factor	ISOVUE-M	Competing nonionic contrast products
Active ingredient	Iopamidol	May use iohexol, iopromide, ioversol, or another agent
Intrathecal positioning	Specific labeled positioning	Varies by product
Excipient complexity	Low	Generally low for aqueous solutions
Patent differentiation	Limited for legacy product	Varies by manufacturer and product age
Purchasing driver	Price, supply, route suitability	Price, supply, route suitability
Commercial moat	Brand, quality systems, distribution, clinical familiarity	Same factors, with varying strength

The relevant competitive advantage is not an unusual excipient. It is a validated product that hospitals can buy consistently and use within established neuroradiology protocols.

What litigation or Paragraph IV activity affects ISOVUE-M?

No specific current Paragraph IV litigation, patent settlement, or active dispute can be stated without a current review of FDA litigation records, ANDA litigation filings, and the Orange Book. For a legacy contrast agent, litigation risk is generally more likely to arise from a new listed formulation or method-of-use patent than from the original iopamidol molecule.

A commercial diligence review should distinguish:

• ANDA patent litigation under the Hatch-Waxman Act.
• Product-liability cases involving contrast-agent adverse events.
• Manufacturing or supply disputes.
• Patent disputes over delivery devices or packaging.
• Antitrust or contracting disputes involving hospital procurement.

These categories have different effects on launch timing and valuation. Patent litigation can delay generic entry. Product-liability litigation can affect insurance, labeling, and customer confidence. Supply disputes can create short-term share shifts without changing underlying patent rights.

What is the revenue exposure and market opportunity for ISOVUE-M?

Bracco does not generally disclose product-level ISOVUE-M revenue in public financial reporting. Revenue exposure therefore cannot be reliably separated from the broader ISOVUE franchise or Bracco's contrast-media business using standard public disclosures.

The commercial opportunity is best assessed through market structure:

1. Intrathecal use is a narrower market than intravenous contrast imaging.
2. The number of technically qualified suppliers is limited by sterile manufacturing and route-specific requirements.
3. Generic pricing pressure is likely once multiple approved suppliers are available.
4. Supply interruptions can produce temporary pricing and share opportunities.
5. Excipient substitution alone is unlikely to create a differentiated premium product.
6. A prefilled, workflow-optimized, or supply-secure presentation may create more commercial value than a new buffer or chelator.

Key Takeaways

• ISOVUE-M is a legacy iopamidol injection for intrathecal myelography.
• Its excipient package consists of tromethamine, edetate calcium disodium, pH adjusters, and Water for Injection.
• The formulation is conventional and does not present an obvious high-value proprietary excipient platform.
• Practical barriers remain significant because the product is sterile, injectable, single-dose, and labeled for intrathecal administration.
• Patent-based exclusivity is likely less important than regulatory approval, manufacturing validation, API supply, packaging, and hospital contracting.
• Biosimilar competition does not apply. Generic competition is the relevant entry threat.
• Commercial opportunities are strongest in sterile contract manufacturing, qualified raw-material supply, prefilled delivery systems, packaging, and supply-chain reliability.
• Product-level ISOVUE-M revenue cannot be isolated reliably from public company disclosures.

FAQs

Can tromethamine be replaced in an iopamidol intrathecal formulation?

Yes, a developer could investigate an alternative buffer, but the change would require formulation, stability, compatibility, safety, and regulatory support. The alternative must be suitable for intrathecal administration and maintain critical quality attributes.

Does ISOVUE-M contain a preservative?

The product is supplied as a single-dose injectable presentation and is labeled without an antimicrobial preservative. This is consistent with the safety expectations for intrathecal administration.

Is ISOVUE-M interchangeable with intravenous iopamidol products?

No automatic interchangeability should be assumed. Route-specific labeling, concentration, excipient composition, osmolality, packaging, and approved indications must be evaluated for each product.

Can a generic manufacturer use the same excipients as ISOVUE-M?

A generic manufacturer may use the same excipients when permitted by the applicable FDA pathway and when the resulting product meets quality, safety, equivalence, and route-specific requirements. Copying excipients does not eliminate sterile-manufacturing or regulatory obligations.

Would a new ISOVUE-M formulation qualify for new patent protection?

Potentially, but patentability would depend on whether the formulation provides a novel and non-obvious composition, stability profile, manufacturing process, delivery system, or clinical advantage. Conventional substitution of one established buffer or chelator is unlikely to provide a strong patent position without unexpected results.

References

1. U.S. Food and Drug Administration. (2023). ISOVUE-M (iopamidol injection) prescribing information. Bracco Diagnostics Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. American College of Radiology. (2024). ACR manual on contrast media. American College of Radiology.

5. Bracco Group. (2024). Annual report and corporate information. Bracco S.p.A.